U.S. Markets
Moderna (MRNA) reiterates it expects 2026 revenue growth of 15% to 25% (prev. 10%), and is on track to achieve approximately 10ppts of gross margin expansion in 2026, excluding the litigation settlement charge
ORIGINAL · NewsquawkModerna (MRNA) reiterates it expects 2026 revenue growth of 15% to 25% (prev. 10%), and is on track to achieve approximately 10ppts of gross margin expansion in 2026, excluding the litigation settlement chargeRead originalHide original
Commercial growth opportunities in 2027 and beyond include: Seasonal influenza European expansion Strategic partnerships Expanded respiratory portfolio Oncology
StockNow breaking-news AI analysis
Moderna reiterated 2026 revenue growth of 15%–25%; the range was raised from up to 10% after third-quarter results beat analyst expectations.
News detail
Commercial growth opportunities in 2027 and beyond include: Seasonal influenza European expansion Strategic partnerships Expanded respiratory portfolio Oncology
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
